Coherus Oncology (CHRS) Operating Expenses (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Operating Expenses data on file, last reported at $48.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 8.62% year-over-year to $48.5 million; the trailing twelve-month figure through Mar 2026 stood at $218.7 million (up 4.67% YoY), and the FY2025 full-year result was $223.3 million, down 1.21% from the prior year.
• Operating Expenses retreated to $48.5 million in Q1 2026, from $58.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $160.4 million in Q4 2023 to a low of $48.5 million in Q1 2026.
• A 5-year average of $83.9 million and a median of $70.1 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 65.66% in 2023 and sank 66.89% in 2024, its largest moves.
• Tracing CHRS's Operating Expenses over 5 years: stood at $96.8 million in 2022, then soared by 65.66% to $160.4 million in 2023, then slumped by 66.89% to $53.1 million in 2024, then grew by 10.38% to $58.6 million in 2025, then declined by 17.34% to $48.5 million in 2026.
• Business Quant data shows CHRS's Operating Expenses at $48.5 million in Q1 2026, $58.6 million in Q4 2025, and $55.9 million in Q3 2025.